Hematology Development News Today

Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM vipivotide tetraxetan) in the pre-chemotherapy setting for patients with...

Improving Quality of Life for Breast Cancer Survivors: The NATALEE Trial

Breast Cancer. NCCN Guidelines. Published March 2023. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf/ Accessed August 2023. European Society...

FRANKFURT: Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25 percent in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but facing strong competition from Eli Lilly. The company on Friday said the relative risk reduction of cancer recurrence was 25.2 percent and that the results were

Novartis breast cancer drug Kisqali cut the risk of recurrence by more than 25% in a pivotal trial on women diagnosed at an early stage, positioning the Swiss drugmaker to win new patients and but... | June 2, 2023

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with... | May 25, 2023

Results from Phase 3 COMMANDS study, selected for ASCO's official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent

Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III... | May 11, 2023

Updated iptacopan data confirm hemolysis control in paroxysmal nocturnal hemoglobinuria (PNH) patients from Phase III APPLY-PNH and APPOINT-PNH studies Head-to-head data from Phase III ASCEMBL trial

BMS is seeking approval of Reblozyl (lupatercept) as a first-line treatment of anemia in adults with lower-risk MDS.